November 2012

From a single campus at Clayton with fewer than 400 students, Monash has grown into a network of campuses, education centres and partnerships spanning the globe. With approximately 60,000 students (and 270,000 alumni) from over 170 countries, we are today Australia’s largest university.

A global healthcare leader, Novartis has one of the most exciting product pipelines in the industry today. A pipeline of innovative medicines brought to life by diverse, talented and performance driven people. All of which makes them one of the most rewarding employers in their field.

The vision of NMIMS University is to define the 21st century technological and management research. Hence the goal for NMIMS University is to encourage excellence in research and publication activities. Research is a precursor to discovery and innovation. The University systems survive on the strength of research i.e. knowledge creation and dissemination system. Realities of the modern world demand interdisciplinary research or research that cuts across the traditional boundaries of discipline.

What do you envision for your future? At GE Healthcare, we strive to see life more clearly. Our "healthymagination" vision for the future invites the world to join us on our journey as we continuously develop innovations focused on reducing healthcare costs, increasing access and improving quality and efficiency around the world.

About Authors:
Mr. Satyanand Tyagi*, Patel Chirag J¹, Asheesh Singh²
*President, Tyagi Pharmacy Association & Scientific Writer (pharmacy), Chattarpur, New Delhi, India-110074.
Prof. Satyanand Tyagi is a life time member of various pharmacy professional bodies like IPA, APTI and IPGA. He has published various research papers and review articles. His academic works include 52 Publications (44 Review Articles and 08 Research Articles of Pharmaceutical, Medicinal and Clinical Importance, published in standard and reputed National and International Pharmacy journals; Out of 52 publications, 11 are International Publications).
He has published his papers almost in different specialization of Pharmacy field...His research topics of interest are neurodegenerative disorders, diabetes mellitus, cancer, rare genetic disorders, psycho-pharmacological agents as well as epilepsy.
¹Department of Pharmaceutics, Maharishi Arvind Institute of Pharmacy, Mansarovar, Jaipur, Rajasthan, India-302020.
²Research Associate, Center for Research and Development, Ipca Laboratories Ltd Ratlam, Madhya Pradesh, India-457114.
*sntyagi9 @yahoo.com, +91-9871111375 / 9582025220

ABSTRACT:
Prior studies have suggested that depressed people with evidence of high inflammation are less likely to respond to traditional treatments for the disorder, including anti-depressant medications and psychotherapy. This study was designed to see whether blocking inflammation would be a useful treatment for either a wide range of people with difficult-to-treat depression or only those with high levels of inflammation. The study employed infliximab, one of the new biologic drugs used to treat autoimmune and inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease. A biologic drug copies the effects of substances naturally made by the body's immune system. In this case, the drug was an antibody that blocks tumour necrosis factor (TNF), a key molecule in inflammation that has been shown to be elevated in some depressed individuals. Study participants all had major depression and were moderately resistant to conventional antidepressant treatment. Each participant was assigned either to infliximab or to a non-active placebo treatment. When investigators looked at the results for the group as a whole, no significant differences were found in the improvement of depression symptoms between the drug and placebo groups. However, when the subjects with high inflammation were examined separately, they exhibited a much better response to infliximab than to placebo.

About Authors:
Hitesh Chopra*
A.S.B.A.S.J.S.M. College Of Pharmacy Bela Ropar.
chopraontheride@gmail.com

Abstract
The first and the second generation type of dosage forms had been found to have lower efficacy of drug reaching to the targeted tissue this lead to need for third generation drug delivery system which contains the liposomes, microspheres, microcapsules, nanodiamonds etc. with these type of drug delivery system it had been found to have better patient compliance and reduced side effects. The present paper  deals with the same as there is first formation of Metformin double emulsion and then precipitation of the drug from the polymeric solution. In this study challenge was to encapsulate Metformin with high entrapment efficiency by w/o/o double emulsion solvent diffusion technique using non-aqueous processing media. The primary requirement of this method to obtain microsphere is that selected solvent for polymer must be immiscible with non aqueous processing media, so to fulfill the requirement.